Diffuse large B-cell lymphoma: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• CD19 42
• CD20 22
• BCL-2 13
• MYC 10
• PD-1 12
• BTK 10
• TP53 7
• PD-L1 3
• CD22 7
• STAT3 0
• CD30 5
• CD47 0
• PI3K 0
• EZH2 1
• LAG-3 0
• ALK 0
• CTNNB1 0
• JAK 0
• STING 0
• BCMA 2
• EGFR 0
• METTL3 0
• mTOR 0
• AKT 0
• CD38 0
• IL-6 0
• JNK 0
• MMP-9 0
• PKM2 0
• PRMT5 0
• TIGIT 1
• TIM-3 0
• ABL1 0
• ARID1A 1
• ATM 0
• BRAF 0
• BRCA1 1
• BRCA2 1
• CCR5 0
• CD40 0
• CDKN2A 0
• CTLA-4 0
• CXCR4 0
• FGFR 0
• FTO 0
• GPX4 0
• HDAC 0
• IL-1 0
• IL-15 0
• MYCN 0
• NLRP3 0
• NOTCH1 1
• PARP 0
• PINK1 0
• PPAR 0
• RAS 0
• SHP2 0
• SIRT1 0
• TERT 0
• TFEB 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 41+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma

  NCT07098364· Fred Hutchinson Cancer Center· Updated 11 Sept 2026

  “Insufficient funding”Registry text, quoted unchanged. Source

• Terminated

  A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

  NCT06256484· Atara Biotherapeutics· Updated 11 Mar 2026

  “Financial reasons”Registry text, quoted unchanged. Source

• Terminated

  Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

  NCT05626322· Pfizer· Updated 5 Sept 2025

  “The trial terminated due to the inability to recruit the planned number of subjects. The decision was not based on any safety and/or efficacy concerns”Registry text, quoted unchanged. Source

• Terminated

  Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

  NCT06343376· Roswell Park Cancer Institute· Updated 3 Aug 2025

  “Manufacturing issues”Registry text, quoted unchanged. Source

• Terminated

  huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia

  NCT03103971· Fred Hutchinson Cancer Center· Updated 10 Apr 2024

  “Terminated due to slow enrollment and end of funding”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

  NCT04512716· Memorial Sloan Kettering Cancer Center· Source

• Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing

  NCT03226704· National Cancer Institute (NCI)· Source

• CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

  NCT06026319· Marcela V. Maus, M.D.,Ph.D.· Source

• A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

  NCT04594642· AstraZeneca· Source

• 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers

  NCT04464200· Memorial Sloan Kettering Cancer Center· Source

• Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma

  NCT05626322· Pfizer· Source

• A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

  NCT02763319· Incyte Corporation· Source

• Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma

  NCT06902012· Zhujiang Hospital· Source

• ENABLE-1 (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)

  NCT04049513· Malaghan Institute of Medical Research· Source

• A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

  NCT04231747· Juno Therapeutics, a Subsidiary of Celgene· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 9
• Mendelian Randomization Analysis 6
• CRISPR-Cas Systems 1
• Gene Expression Profiling 49
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 2
• Exome Sequencing 3
• Proteomics 4
• Flow Cytometry 7
• Immunohistochemistry 36
• Liquid Biopsy 1
• Circulating Tumor DNA 12
• Xenograft Model Antitumor Assays 30
• Positron-Emission Tomography 15
• Magnetic Resonance Imaging 28
• Machine Learning 11
• Deep Learning 9
• Cohort Studies 15
• Genome-Wide Association Study 4

• Exploring Potential Multi-Target Inhibition Mechanisms of Ganoderma lucidum Against EBV-Mediated DLBCL Using Integrative Bioinformatics, Machine Learning, and Network Pharmacology Approaches.

  J Food Sci, Oct 2026

• A machine learning-derived sarcopenia index is associated with survival and nonrelapse mortality in DLBCL.

  Blood Adv, Sept 2026

• Integrated Clinical-Molecular Risk Stratification in Diffuse Large B-Cell Lymphoma: Machine Learning Survival Analysis.

  JMIR Med Inform, Aug 2026

• Identifying Distinct Molecular Subtypes and Establishing a Prognostic Framework for DLBCL Patients via Multiomics Analysis and Machine Learning Approaches.

  Hum Mutat, Jul 2026

• Machine learning-driven investigation on liquid-liquid phase separation-related prognostic signature in diffuse large B-cell lymphoma.

  Br J Haematol, Jun 2026

• Cell-free chromatin state tracing reveals disease origin and therapy responses.

  Nature, Mar 2026

• Machine learning based on clinical and gene expression data assists in survival prediction and treatment optimization for diffuse large B-Cell lymphoma patients.

  Ann Hematol, Feb 2026

• Integrating machine learning and molecular simulations for the design of potent HDAC2 inhibitors in diffuse large B-cell lymphoma.

  Comput Biol Chem, Feb 2026

• Potential link between dioxin induced progression of diffuse large B-cell lymphoma: New insights from machine learning and in vitro experiments.

  Ecotoxicol Environ Saf, Jan 2026

• Predictive biomarkers validation of CD3+ cell apheresis yield in CAR-T manufacturing for diffuse large B-cell lymphoma: a machine learning approach.

  Sci Rep, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.